Loading
TGFB1 (Transforming growth factor beta-1 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively. Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-1 and regulates its activation via interaction with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS, that control activation of TGF-beta-1.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes clinical 0.58, affected pathway 0.83, literature 1.00, genetic association 0.16, animal model 0.57).
In plain words · TGFB1 (Transforming growth factor beta-1 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
TGFB1 (Transforming growth factor beta-1 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.
No product in this corpus aims at TGFB1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA TGFB1: RNA low tissue specificity; no normal tissue stained high; highest cancer staining liver cancer (1 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (myelodysplastic syndrome). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas TGFB1 tissue; Open Targets ENSG00000105329 associations
First described 1985. Earliest sequence paper UniProt cites for the protein: Derynck et al, Nature, 1985, "Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells". Source.
Sources: HGNC HGNC:11766 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01137 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000105329 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: myelodysplastic syndrome 0.58 (GraphQL API, CC0))
Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively. Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-1 and regulates its activation via interaction with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS, that control activation of TGF-beta-1. Interaction with LRRC33/NRROS regulates activation of TGF-beta-1 in macrophages and microglia. Interaction with LRRC32/GARP controls activation of TGF-beta-1 on the surface of activated regulatory T-cells (Tregs). Interaction with integrins (ITGAV:ITGB6 or ITGAV:ITGB8) results in distortion of the Latency-associated peptide chain and subsequent release of the active TGF-beta-1. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 19q13.2 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
No normal tissue stained high.
Medium only: breast cancer, cervical cancer, endometrial cancer, ovarian cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
It is the clearest mechanistic answer to why microsatellite-stable colorectal cancer resists immunotherapy, and the rationale for every TGF-beta plus checkpoint combination now in trials in this disease.
It made TGF-beta the central target of the microsatellite-stable half of the disease, which is the line that leads to Tauriello's immune-evasion work and to the TGF-beta plus checkpoint combinations in trials.
The CMS framework organises colorectal cancer biology and trial stratification; BRAF V600E tumours cluster in CMS1, and CMS4's shorter survival and stromal signalling are targets of ongoing research.
Query for this target: (TITLE:"TGFB1" OR ABSTRACT:"TGFB1" OR TITLE:"transforming growth factor beta 1" OR ABSTRACT:"transforming growth factor beta 1" OR TITLE:"Transforming growth factor beta-1 proprotein" OR ABSTRACT:"Transforming growth factor beta-1 proprotein" OR TITLE:"TGFbeta" OR ABSTRACT:"TGFbeta" OR TITLE:"DPD1" OR ABSTRACT:"DPD1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TGFB1, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform, Colorectal cancer.
Shares Stromal gene expression defines poor-prognosis subtypes in colorectal cancer, TGF-β signalling, Open Targets Platform, Colorectal cancer.
Shares TGF-β signalling, Open Targets Platform, Colorectal cancer.
Shares TGF-β signalling, Open Targets Platform, Colorectal cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.